Fluidigm Corporation is a Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies.
Fluidigm Corporation (FLDM) had a good day on the market for Wednesday March 31 as shares jumped 4.63% to close at $4.52. About 1.48 million shares traded hands on 7,568 trades for the day, compared with an average daily volume of n/a shares out of a total float of 74.55 million. After opening the trading day at $4.30, shares of Fluidigm Corporation stayed within a range of $4.69 to $4.26.
With today’s gains, Fluidigm Corporation now has a market cap of $336.95 million. Shares of Fluidigm Corporation have been trading within a range of $12.45 and $1.67 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm’s revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.
Fluidigm Corporation is based out of South San Francisco, CA and has some 627 employees. Its CEO is Stephen Christopher Linthwaite.